300
Participants
Start Date
November 26, 2015
Primary Completion Date
January 19, 2021
Study Completion Date
January 17, 2024
Plerixafor
Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) \[3\]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
A.O.U. Città della Salute e della Scienza di Torino, Torino
Fondazione EMN Italy Onlus
OTHER